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B lymphocytes are part of the inflammatory cells recruited to
the human kidney in various disease settings. B cell infiltrates
have been described in renal allografts, in acute and chronic
interstitial nephritis, and the most common glomerular
diseases like immunoglobulin A (IgA) and membranous
nephropathy. These cells are almost exclusively recruited to
the tubulointerstitium, but not the glomerular tuft. In
addition to diffuse tubulointerstitial infiltrates, B cells
together with T cells and dendritic cells form organized
nodular aggregates surrounded by neo-lymphatic vessels.
The functional significance of these tertiary lymphoid organs
remains to be fully defined. Intrarenal B cells may be part of a
local system to enhance the immunological response by
functioning as antigen presenting cells, and as a source for
cytokines promoting T-cell proliferation and lymphatic
neoangiogenesis. In this way, they could enhance the local
immune response to persisting autoantigens in the
tubulointerstitium.
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B cells play a pivotal role in immune response as they survey
the body for the presence of ‘non-self ’ antigens, present
antigens to T lymphocytes, and produce antibodies as
effector cells.1 The mature B cells catch antigen via their
B-cell receptors, which results in antigen uptake, the
development of germinal centers, and formation of high
affinity antibodies.2 The interaction between B cells and
T cells includes primed T cells activation of B cells (via
costimulatory molecules), and B cell stimulation of T cells to
release cytokines.2,3 Most B-cell responses to antigens require
involvement of dendritic cells (DCs) and antigen-specific
T helper cells. T-cell-dependent responses result in short-
lived plasma cell differentiation, germinal center develop-
ment of long-lived plasma cells, and B memory cells.4
Additionally, B cells release a plethora of cytokines,
chemokines and growth factors, and are involved in lympho-
and lymphangio-neogenesis, that is, the formation of
lymphoid tissue and lymphoid vessels.5–7
Secondary lymphoid organs, that is lymph nodes, Peyer’s
patches, tonsils, and the white pulp of the spleen, are
localized strategically in the body to allow a rendezvous
between antigen, antigen presenting cells, and lymphocytes
and enable effective immune responses.8 Structures with a
similar complex microarchitecture, but present in chronically
inflamed organs, are referred to as ‘tertiary lymphoid organs’
(TLOs).9 Chemokines are involved in the positioning of the
interacting cell types in lymphatic microenvironments. Naive
B cells re-circulate and localize to B-cell follicles in secondary
lymphoid organs due to their expression of CXCR5 and the
expression of the corresponding ligand CXCL13/BLC by
follicular stromal cells.10,11 After encountering their specific
antigen, B cells rapidly re-localize to the B/T-cell boundary
area, which is mediated by their rapid induction of CCR7,
while CXCR5 remains expressed.12 The expression of CCR7
by B cells and T cells enables them to meet. CXCL13/BLC and
CXCR5 knockout mice were found to be severely deficient in
lymph nodes and Peyer’s patches, indicating a role during
lymph-organogenesis.12 CXCR4 and its corresponding ligand
CXCL12/SDF-1 also play a role in B lymphopoiesis, as the
knockout animals demonstrated a severe B-cell deficiency.13
Until recently, the renal literature has focused on the role
of B cells as antibody-producing cells particularly in
immune-complex diseases and transplant rejection. Lately,
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the availability of antibodies, which deplete CD20-positive
B cells, has sparked great interest in their use in autoimmune
diseases and has rekindled interest in the role of B cells in
various clinical settings.14 Both animal experiments as well
as clinical observations point toward a significant impact of
B lymphocytes beyond antibody formation in chronic
progressive diseases. For example, in a mouse model of toxic
liver injury, a deficiency of B cells improved liver fibrosis,
which was not T cell or antibody dependent.15 In the MRL/
lpr model of lupus nephritis, mice expressing a membrane
bound immunoglobulin (which therefore had B cells but
were unable to secrete immunoglobulins) developed a
nephritis in the absence of immune-complex deposition.16
Both studies clearly illustrate a role of B cells in tissue injury
independent of antibody formation. In cases of deteriorating
renal allografts with vascular rejection, but without signs of
antibody-mediated injury (C4d negative), a single dose of
anti-CD20 antibody improved allograft function, and was
associated with the disappearance of follicular B cell
aggregates in the allograft.17 B cells are recruited to most
chronically inflamed tissues and the formation of TLOs has
been described in chronic diseases involving such diverse
organs as lung, thyroid, and synovia.18 Their pathophysio-
logical significance remains to be clearly defined. At present,
antibody depletion of CD20-positive B cells has been mostly
used in immune-complex-mediated diseases such as systemic
lupus erythematodes, mixed cryoglobulinemia, and mem-
branous nephropathy; therefore, the role of local B-cell
accumulation versus reduction of antibody formation cannot
be addressed by these studies.14
B CELLS IN RENAL ALLOGRAFTS
A study by Sarwal et al.19 on a relatively small group of
pediatric renal allograft recipients sparked renewed interest in
the role of B cells in renal allograft survival. They described
an association between the presence of nodular B-cell
aggregates in the graft and steroid resistance, resulting in a
poor transplant outcome.19 A number of additional reports
have noted B-cell infiltrates and nodular B-cell structures in
renal transplants. Tsai et al.20 described 45 biopsies taken
from 31 pediatric patients, in which higher numbers of
CD20-positive B cells were associated with poor outcome.
The presence of B cells was associated with acute cellular, but
not with antibody-mediated rejection.20 In contrast, Mengel
et al.21 found no association between B cells and outcome in
a series of 833 protocol and 306 indicated biopsies. The only
predictor of allograft outcome was persistent inflammation
in sequential biopsies, irrespective of the type of infiltrate.21
In a series of 120 renal allograft biopsies, Kayler et al.22
demonstrated that CD20-positive B cells were common in
renal allografts, and clusters of B cells were found in 71 (59%)
of the biopsies. Acute cellular rejection was more frequent in
the group with lymphoid aggregates (96 versus 80%,
P¼ 0.0051). No significant differences were detected in the
groups with and without aggregates in terms of time to
rejection, steroid resistance, serum creatinine, or graft loss.22
While all series noted the accumulation of B cells at times in
lymphoid structures, the impact on allograft survival remains
controversial.
Single doses of rituximab given to 49 renal allograft
recipients in combination with conventional triple immuno-
suppressive therapy led to a complete depletion of B cells
from peripheral blood in 88% of the patients persisting over
15 months in the majority of patients. The B cells were
completely eliminated in kidney tissue and reduced in lymph
nodes.23 There was no control group in this study; therefore,
the impact of rituximab treatment was not evaluated.
Steinmetz et al.24 studied serial sections of 23 allograft
biopsies for the expression CD20, CXCR5, and CXCL13/BLC.
Acute rejection was found in 13 biopsies, four of which
contained clusters of CD20-positive B cells.24 As described in
the introduction, B cells migrate to and are positioned in
secondary lymphoid organs mediated by the expression of
CXCR5 on B cells and CXCL13/BLC by follicular stromal
cells. Biopsies with acute rejection demonstrated a signifi-
cantly increased expression of CXCL13/BLC as compared to
non-rejecting allografts. By immunohistochemistry sites of
CXCR5-positive cells correlated with the expression of
CXCL13/BLC, and both were restricted to sites of nodular
B-cell accumulation.24 Unfortunately, the induction pathways
as well as the exact cellular source of CXCL13/BLC in the
kidney have not yet been identified.25 Kerjaschki et al.26
further described TLOs in renal allografts associated with
newly formed lymphatic vessels containing CD4- and CD8-
positive T cells, S100-positive DCs, and CD20-positive B
lymphocytes. A high number of CCR7-positive cells within
TLOs were associated with expression of the ligand CCL21/
secondary lymphatic chemokine. Podoplanin expression on
lymphatic endothelial cells has been suggested to serve as a
binding structure for chemokines produced by or transported
to lymphatic endothelium. It was speculated that lymphatic
neo-angiogenesis could contribute to the export of infiltrat-
ing cells and also might be involved in an alloreactive
response.26
INTRARENAL B CELLS IN PATIENTS WITH KIDNEY DISEASE
Very little is known about the role of B cells as part of the
infiltrate in the human kidney. Small biopsy series, mostly
from the 1980s, described a percentage of 2–27% of the
interstitial leukocyte infiltrates as being B cells.27 Using the
marker PHM14, 8% of the interstitial leukocytes in IgA
nephropathy and 12% in interstitial nephritis were identified
as B cells and correlated with renal function.27 In contrast,
using CD20 as a B cell marker, we described a prominent
accumulation of B cells in primary interstitial diseases as well
as in the secondary interstitial involvement of IgA and
membranous nephropathy.28,29 CD20-positive B cells were
seen as diffuse infiltrates, but in about 30% of cases they
formed TLOs together with T cells. The B cells were located
in the center of the aggregates, reminiscent of follicles in
lymph nodes. These follicular aggregates were associated with
expression of CXCL13/BLC and of CXCR5 on B cells
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comparable to the results in renal allografts.24,26 The TLOs
were also surrounded by neolymphatics.25 It may be of
interest in this context that we have reported the presence of
small blood vessels positive for the chemokine receptor
DARC in areas of chronic renal interstitial inflammation,
including failing transplants.30,31 DARC is expressed on high
endothelial venules in secondary lymphoid organs, the site of
lymphocyte recirculation.32 DARC-positive vessels were
commonly found in the center of tertiary lymphoid follicles,
with a typically high endothelium.30 These DARC-positive
vessels are considered to represent the site of leukocyte
emigration from the circulation into the tubulointerstitium.
WHAT COULD BE THE SIGNIFICANCE OF TLOs IN THE KIDNEY?
Immune responses are aimed at the eradication of antigens,
and perhaps also—as part of the danger signal hypothesis—
at the removal of damage associated molecular pattern
molecules. Failure to do so with antigen or damage associated
molecular pattern persistence would promote chronic
inflammation with an accumulation of T cells, macrophages,
B cells, DCs, and plasma cells.18 In many tissues with chronic
inflammation, it has been noted that from an initially diffuse
infiltrate, leukocytes organize into structures resembling
secondary lymphoid organs, termed lymphoid neogenesis
(Figure 1).
These have been described in the thyroid in Hashimoto
thyroiditis and Grave’s disease, in the synovia of rheumatoid
arthritis, in salivary glands in Sjo¨gren’s disease, in multiple
sclerosis, in inflammatory bowl diseases, in lung diseases, and
in allografts (for example, heart).18,33 Chronic kidney diseases
and renal allograft dysfunction can now be added to this
list.26,28,29 Although the constituents are the same as in lymph
nodes, TLOs differ in that they do not have afferent
lymphatics nor a fibrillar stroma or a capsule. Thereby, they
are more comparable to mucosa-associated lymphatic tissue.
Figure 1 represents an adaptation to the kidney of a general
scheme proposed for the development of TLOs.18 In this
scheme, tertiary lymphoid follicles are considered as dynamic
structures developing from scattered leukocyte infiltrates to
aggregates and eventually into organized lymphoid structures
containing high endothelial venules surrounded by neolym-
phatic vessels. The initiation of an inflammatory response in
the tubulointerstitium may occur by activation of tubular
epithelial cells and/or resident monocyte/DCs. Some of the
latter travel to the regional lymph nodes, activating and
priming lymphocytes to elicit a response to the specific
antigenic stimuli. The primed lymphocytes are in turn
recruited into the tubulointerstitium (Figure 1a). In contrast
to the conventional model, antigen-bearing renal DC (that is,
from the DC network) may not receive cues to traffic out of
the kidney after taking up antigen. Thus, renal DC may
scavenge and present antigen for recognition within the renal
interstitial compartment of the kidney. With chronic antigen
stimulation, this may initiate the formation of lymphoid-like
follicles when lymphocytes encounter these DC (Figure 1b
and c). Ishikawa et al. described expression of CXCL13 in
kidneys with lupus nephritis by mature myeloid DCs in the
(NZBNZW)F1 model.34 This would then be followed by B
cells joining in and thus the establishment of a local
lymphoid follicle that is ideally situated to closely surveille
the tubulointerstitium.
In the early phase (Figure 1a), activation of intrinsic renal
cells is mediated by proinflammatory cytokines (for example,
interferon-g, interleukin-1b, and tumor necrosis factor), by
ischemia, damage associated molecular pattern molecules
released from damaged cells or matrix, complement compo-
nents, immune complexes, reactive oxygen species, and so on.
The inflammatory response might promote the detection
of tubulointerstitial antigens as autoantigens, leading to a
persisting interstitial inflammatory response (Figure 1b). For
the development of lymphoid tissue and organized tertiary
lymphoid structures in other organs, the expression of
lymphotoxina1b2 and interaction with lymphotoxin-b
receptor on stromal cells has been shown to be a crucial
step (Figure 1b).18,35 Lymphotoxin1b2 promotes the forma-
tion of follicular DCs, which in turn release CXCL13/BLC
promoting germinal center formation. Follicular DCs have
not yet been described in detail during human renal
inflammation, so further studies are clearly needed. The role
of chemokines in the formation of TLOs has recently been
reviewed by Steinmetz et al.25 in detail. The release of
lymphoid chemokines, such as CCL19/ELC and CCL21/SLC,
favors the development of T-cell accumulation (Figure 1c).
Further recruitment of T and B lymphocytes might be
supported by the phenotypical change of peritubular
capillaries into vessels with a plumb endothelium, reflecting
high endothelial venules that allow recruitment of naive
lymphocytes. The chemokine-binding protein DARC on the
endothelium of these vessels might be involved in chemokine
trafficking and presentation.30 In other organs, ectopic
germinal centers contain proliferating B cells in all stages of
B-cell development, from centroblasts to plasma cells,
indicating the functionality of these structures.36 The
microarchitecture of TLOs with B-cell follicles and a T-cell
paracortex may enable optimal sampling of antigen by naive
lymphocytes. Aloisi and Pujol-Borrel18 hypothesized that the
advantage of TLOs might be that in the case of an unsuccessful
immune response in lymph nodes, it might increase the
availability of antigen when the involved cell types are recruited
to the site of injury. In the tubulointerstitium of the kidney,
chronic inflammation, irrespective of the initial inciting
mechanism, might pave the way for a misguided immune
response in which interstitial antigens might become detected as
‘dangerous’. On the other hand, lymphoid follicles might also
favor the formation of regulatory T cells and may thus help to
keep in bay potential local autoimmune reactions. Like in many
other immunological reactions, the formation of intrarenal
lymphoid follicles per se may be neither detrimental nor
beneficial, but rather a sign of a chronic local inflammatory
process that, depending on the momentaneous balance between
pro- and anti-inflammatory cytokines and chemokines, will
activate or suppress an inflammatory immune response.
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TREATMENT OF RENAL DISEASES WITH ANTI-CD20
APPROACHES
Rituximab is a chimeric antibody that binds to the CD20
molecule expressed on immature and mature B cells, but not
on plasma cells.14 In addition to the elimination of
circulating- and likely tissue-associated B cells (via comple-
ment-dependent cytotoxicity and antibody-dependent cell
toxicity), the blockade of Fc-g receptor expressing cells has
also been suggested as a potential therapeutic mechanism
(‘decoy hypothesis’).37 B-cell depletion usually persists for
about 6–9 months but shows a high variability.14 Other
biologicals, such as tumor necrosis factor-blocking agents,
might also interfere with B-cell functions, but this is
beyond the scope of this review. Anti-CD20 treatment in
renal diseases has recently been reviewed.14 ‘Off-label’
applications of rituximab have been reported in membranous
nephropathy (including idiopathic forms, as well as those
occurring in renal allografts, and after stem cell transplanta-
tion), in cryoglobulinemia with renal involvement, in ANCA
associated vasculitis, and in systemic lupus erythematodes.14
The Food and Drug Administration has issued a safety alert
(http://www.fda.gov/bbs/topics/NEWS/2006/NEW01532.html)
after two patients treated with rituximab for systemic lupus
erythematodes developed progressive multifocal leukoence-
phalopathy. This most serious side effect will have significant
impact on the field. It will require very close follow-up of
cases treated so far with a clear-cut definition of the potential
risk.14,38 The anecdotal, non-controlled reports on some
beneficial effects of rituximab treatment, for example in
membranous nephropathy, have to be considered in view of
the safety alert. Should controlled trials on renal disease
eventually be performed, it would be important to also
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Figure 1 | Hypothetical scheme of the development of TLOs in the kidney during chronic injury. This has been detailed according
to the review by Aloisi and Pujol-Borrel18 and is mainly based on extrarenal data on the formation of tertiary lymphatic organs. After an initial
insult (a) inflammatory cells are recruited and promote further inflammation. (b) With the progression of chronic renal injury, macrophages,
B cells, T cells, and potentially DCs accumulate in the tubulointerstitium. During interstitial injury, release of modified tubulointerstitial
antigens might promote persisting inflammation. (c) With the interaction between intrinsic renal cells and interstitial inflammatory cells,
tertiary lymphatic organs form, surrounded by newly formed lymphatic vessels.
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evaluate the presence and fate of intrarenal B cells with the
anti-CD20 therapy, and their relation to clinical outcome.
Unfortunately, our understanding about the role of intrarenal
B cells at this point may be too limited to be applied to the
therapy of human diseases. Certainly, animal experiments
should help to provide some more direct evidence about the
role(s) of intrarenal B cells, especially in terms of progression
of renal diseases.
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